Scarica l'app Stockscreener
1.25
0.79%
-0.01
Dopo l'orario di chiusura:
1.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRBU Giù?
Forum
Previsione
Precedente Chiudi:
$1.26
Aprire:
$1.26
Volume 24 ore:
922.29K
Relative Volume:
0.85
Capitalizzazione di mercato:
$113.47M
Reddito:
$34.48M
Utile/perdita netta:
$-102.07M
Rapporto P/E:
-0.8562
EPS:
-1.46
Flusso di cassa netto:
$-104.90M
1 W Prestazione:
-11.35%
1M Prestazione:
+17.92%
6M Prestazione:
-21.38%
1 anno Prestazione:
-21.38%
Intervallo 1D:
$1.22
$1.32
Intervallo di 1 settimana:
$1.22
$1.43
Portata 52W:
$0.66
$2.9995
Caribou Biosciences Inc Stock (CRBU) Company Profile
Nome
Caribou Biosciences Inc
Settore
Industria
Telefono
510-982-6030
Indirizzo
2929 7TH STREET, SUITE 105, BERKELEY
Confronta CRBU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.25 | 113.47M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-11-08 | Iniziato | Cantor Fitzgerald | Neutral |
| 2023-10-31 | Iniziato | Evercore ISI | Outperform |
| 2023-07-11 | Iniziato | Truist | Buy |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-17 | Iniziato | BofA Securities | Buy |
| 2021-08-17 | Iniziato | Citigroup | Neutral |
| 2021-08-17 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Caribou Biosciences Inc Borsa (CRBU) Ultime notizie
Investors Can Still File Late Claims in Caribou Bioscience Settlement — Here’s How to Get Your Share - TradingView
Caribou Biosciences Confirms Director Elections and Auditor - TipRanks
Analysts Offer Predictions for CRBU FY2026 Earnings - Defense World
Caribou Biosciences (NASDAQ:CRBU) versus AlloVir (NASDAQ:ALVR) Critical Contrast - Defense World
Public Employees Retirement System of Ohio Takes $222,000 Position in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Nuveen Asset Management LLC Acquires 63,096 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionCRBU - ACCESS Newswire
Millennium Management LLC Has $1.37 Million Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Ameriprise Financial Inc. Purchases New Position in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Acquired by Two Sigma Investments LP - Defense World
Bank of America Corp DE Sells 2,800,953 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences, Inc. (NASDAQ:CRBU) Holdings Lowered by Jane Street Group LLC - Defense World
Northern Trust Corp Boosts Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Caribou Biosciences CEO Fireside Chat: Latest CRISPR Innovations at Jefferies Conference - Stock Titan
Caribou Biosciences’ SWOT analysis: biotech stock faces pivotal moment By Investing.com - Investing.com South Africa
Caribou Biosciences’ SWOT analysis: biotech stock faces pivotal moment - Investing.com
Caribou Biosciences (CRBU) Is Paying a $3.9M Settlement to Investors — Here’s How to Get Your Share - TradingView
Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Anti-CD152 Antibody Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Precision Biosciences, TG Therapeutics, RemeGen, Caribou Biosciences - Barchart.com
Shareholders that lost money on Caribou Biosciences, Inc.(CRBU) should contact Levi & Korsinsky about pending Class ActionCRBU - ACCESS Newswire
Crispr Therapeutics Products 2025: Therapies, MOA Insights, - openPR.com
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates - MSN
Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $9.33 - Defense World
Cantor Fitzgerald Analysts Lower Earnings Estimates for CRBU - Defense World
Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know - MSN
Dimensional Fund Advisors LP Sells 321,867 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Barclays PLC Grows Stock Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences Reports Q1 2025 Financial Results - TipRanks
Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU - ACCESS Newswire
Investors who lost money on Caribou Biosciences, Inc.(CRBU) should contact Levi & Korsinsky about pending Class ActionCRBU - ACCESS Newswire
Caribou Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU - ACCESS Newswire
Analysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (AVAH), Caribou Biosciences (CRBU) and Cidara Therapeutics (CDTX) - The Globe and Mail
Shareholders that Lost Money on Caribou Biosciences, Inc. (CRBU) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
RBC Lowers Price Target on Caribou Biosciences to $10 From $11, Keeps Outperform, Speculative Risk - marketscreener.com
Envestnet Asset Management Inc. Grows Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
News: CMN Weekly (9 May 2025)Your Weekly CRISPR Medicine News - CRISPR Medicine News
Caribou Biosciences earnings beat by $0.02, revenue topped estimates - Investing.com Canada
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Comparing Invizyne Technologies (NASDAQ:IZTC) and Caribou Biosciences (NASDAQ:CRBU) - Defense World
Ratio Revelations: Caribou Biosciences Inc (CRBU)’s Financial Metrics in the Spotlight - DWinneX
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference - The Manila Times
Leading CRISPR Company Caribou Biosciences to Reveal Latest Pipeline Updates at Major Healthcare Conference - Stock Titan
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
Caribou Biosciences (CRBU) to Release Quarterly Earnings on Tuesday - Defense World
Levi & Korsinsky Notifies Shareholders of Caribou Biosciences, Inc.(CRBU) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Investors Can Still File Late Claims for Caribou Biosciences $3.9M Settlement Payouts - TradingView
HC Wainwright Issues Optimistic Forecast for CRBU Earnings - Defense World
Caribou Biosciences Inc [CRBU] Records 200-Day SMA of $1.6979 - knoxdaily.com
Taking the lead: Caribou Biosciences Inc (CRBU) - Sete News
Caribou Biosciences Inc Azioni (CRBU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Caribou Biosciences Inc Azioni (CRBU) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MCCLUNG BARBARA G | Chief Legal Officer |
Feb 21 '25 |
Sale |
1.35 |
3,564 |
4,811 |
443,502 |
| Khan Ruhi Ahmad | Chief Business Officer |
Feb 21 '25 |
Sale |
1.35 |
3,564 |
4,811 |
66,936 |
| Kanner Steven | Chief Scientific Officer |
Feb 21 '25 |
Sale |
1.35 |
3,564 |
4,811 |
431,556 |
| Ryali Sriram | Chief Financial Officer |
Jan 29 '25 |
Buy |
1.42 |
17,360 |
24,651 |
17,360 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):